Breaking News Instant updates and real-time market news.

NBRV

Nabriva Therapeutics

$1.90

0.12 (6.74%)

07:11
10/15/19
10/15
07:11
10/15/19
07:11

Nabriva Therapeutics to present data from Phase 3 trials of XENLETA

Nabriva Therapeutics announced that it will present data on the pooled results from completed Phase 3 trials of XENLETA at the CHEST Annual Meeting 2019. XENLETA is a pleuromutilin antibiotic for the intravenous and oral treatment of community-acquired bacterial pneumonia in adults and is now commercially available in the United States. Results from the pivotal Lefamulin Evaluation Against Pneumonia 1 and LEAP 2 Phase 3 clinical trials will be featured in three e-poster presentations during a moderated grand-rounds session at the CHEST meeting. These studies demonstrated that XENLETA is a well-tolerated, new IV and/or oral antimicrobial monotherapy for the empiric treatment of adults with CABP and a clinical alternative to moxifloxacin, a current standard of care fluoroquinolone. The data also showed that early clinical response rates of XENLETA, as well as health-related quality of life improvements, were high and similar to that of moxifloxacin in at-risk groups, including patients age 65 years or greater, who are at the highest risk of morbidity and mortality. Details for the upcoming presentations are as follows: Title: Efficacy of Lefamulin Versus Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia: Results of the Lefamulin Evaluation Against Pneumonia 1 And LEAP 2 Double-Blind Noninferiority Phase 3 Clinical Trials. This pooled efficacy assessment of the LEAP 1 and 2 studies reported the early clinical response at 96 +/- 24 hours after first dose of study drug among 1289 randomized patients, and the investigator assessment of clinical response at test-of-cure: five to 10 days after last dose of study drug in the modified intent-to-treat population - those receiving greater than or equal to1 dose of study drug and in the clinically evaluable populations. In addition to efficacy overall, analyses stratified by Pneumonia Outcomes Research Team Risk Class, from both pooled and individual trials, were presented. CABP patients treated with lefamulin demonstrated high response rates for ECR and IACR and was noninferior to moxifloxacin. Response rates with lefamulin IV and/or oral therapy remained high across the indices of severity. Title: Safety and Tolerability of Lefamulin Versus Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia: Results of the Lefamulin Evaluation Against Pneumonia 1 and LEAP 2 Double-Blind Noninferiority Phase 3 Clinical Trials. The objective of this pooled safety assessment of the LEAP 1 and 2 studies was to identify treatment-emergent adverse events among patient groups treated with lefamulin versus moxifloxacin. Pooled data from the LEAP 1 and LEAP showed similar safety and tolerability profiles for lefamulin and moxifloxacin. Title: Efficacy and Safety of Lefamulin Versus Moxifloxacin for Atypical Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia: Pooled Results from the Lefamulin Evaluation Against Pneumonia 1 and LEAP 2 Double Blind Noninferiority Phase 3 Clinical Trials. This analysis was to determine the safety and efficacy of lefamulin versus moxifloxacin in patients with atypical respiratory pathogens including Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydophila pneumoniae. In the pooled patient population, short-course therapy with lefamulin for atypical pathogens resulted in high ECR responder and IACR success rates and was generally well tolerated in comparison to moxifloxacin.

  • 22

    Oct

  • 23

    Oct

NBRV Nabriva Therapeutics
$1.90

0.12 (6.74%)

05/13/19
HCWC
05/13/19
NO CHANGE
HCWC
H.C. Wainwright affirms Buy on Nabriva ahead of expected Lefamulin approval
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $7 price target on Nabriva Therapeutics as he expects Lefamulin's FDA approval for the treatment of community-acquired bacterial pneumonia around its August 19 PDUFA date. Additionally, the analyst expects Lefamulin's EU approval in mid-2020.
08/16/19
HCWC
08/16/19
NO CHANGE
HCWC
H.C. Wainwright sees Q2 2020 approval for Nabriva's Contepo
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $7 price target on Nabriva Therapeutics after the company's announced its plan to resubmit its New Drug Application, or NDA, of Contepo. The analyst sees an approval decision in Q2 of 2020, assuming the NDA is resubmitted in early Q4 of19 as planned. Arce added that it was important that "the FDA did not request new clinical or non-clinical data, nor specify any concerns regarding Contepo's safety or efficacy in the Type A meeting minutes."
08/20/19
HCWC
08/20/19
NO CHANGE
Target $8
HCWC
Buy
Nabriva Therapeutics price target raised to $8 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Nabriva Therapeutics and raised his price target to $8 from $7 after the company's Xenleta received FDA approval to treat adults with community-acquired bacteria pneumonia. With the approval, Xenleta becomes the first IV and oral antibiotic with a novel mechanism of action approved by the FDA for CABP in almost two decades, Arce tells investors in a research note. The analyst believes Xenleta's IV to bio-equivalent oral formulation could enable physicians to seamlessly transition a patient's treatment from the in-patient setting to oral dosing that may be self-administered upon discharge.
09/10/19
NORL
09/10/19
NO CHANGE
NORL
Outperform
Northland sees peak global sales of Nabriva's Xenleta at $1B
Northland analyst Carl Byrnes told investors in a research note that oral and IV formulations of Nabriva Therapeutics' XENLETA are now commercially available in the U.S. through major specialty distributors and is also under review in the EU, with anticipated approval in 12-to-15 months. Byrnes forecasts peak global sales of XENLETA at $1B, supported by XENLETA's clinical differentiation and oral/IV dosing forms. The analyst has an Outperform rating on shares of Nabriva.

TODAY'S FREE FLY STORIES

PAG

Penske Automotive

$51.36

0.015 (0.03%)

17:13
11/13/19
11/13
17:13
11/13/19
17:13
Syndicate
Breaking Syndicate news story on Penske Automotive »

Penske Automotive files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LLY

Eli Lilly

$112.85

-0.31 (-0.27%)

17:12
11/13/19
11/13
17:12
11/13/19
17:12
Hot Stocks
FDA committee says benefits of empagliflozin do not outweigh risks »

The FDA Endocrinologic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

PRTH

Priority Technology

$3.24

-0.03 (-0.92%)

17:08
11/13/19
11/13
17:08
11/13/19
17:08
Earnings
Priority Technology reports Q3 EPS (9c), one estimate (12c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPZ

Domino's Pizza

$279.24

1.185 (0.43%)

17:07
11/13/19
11/13
17:07
11/13/19
17:07
Hot Stocks
Domino's Pizza's Goldman sells 2,486 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 11

    Dec

  • 12

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

17:04
11/13/19
11/13
17:04
11/13/19
17:04
Periodicals
WeWork reported $1.25B loss in Q3, NY Times reports »

WeWork (WE) lost $1.25B…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$6.27

0.31 (5.20%)

17:02
11/13/19
11/13
17:02
11/13/19
17:02
Initiation
GlycoMimetics initiated  »

GlycoMimetics resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$485.67

-1.24 (-0.25%)

17:00
11/13/19
11/13
17:00
11/13/19
17:00
Hot Stocks
BlackRock CFO sells nearly 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ARVN

Arvinas

$28.35

1.85 (6.98%)

16:58
11/13/19
11/13
16:58
11/13/19
16:58
Initiation
Arvinas initiated  »

Arvinas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$17.09

-0.04 (-0.23%)

16:57
11/13/19
11/13
16:57
11/13/19
16:57
Recommendations
FireEye analyst commentary  »

FireEye unique offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

CSCO

Cisco

$48.44

0.06 (0.12%)

16:54
11/13/19
11/13
16:54
11/13/19
16:54
Hot Stocks
Cisco says cyber security is a top priority for customers »

Says innovation pipeline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 09

    Dec

  • 10

    Dec

JPM

JPMorgan

$128.49

-0.65 (-0.50%)

16:54
11/13/19
11/13
16:54
11/13/19
16:54
Periodicals
JPMorgan's new HQ plan clears path for another NYC tower, Bloomberg says »

JPMorgan's plan to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 14

    Jan

SIBN

SI-Bone

$17.88

0.14 (0.79%)

16:53
11/13/19
11/13
16:53
11/13/19
16:53
Syndicate
Breaking Syndicate news story on SI-Bone »

SI-Bone files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLI

RLI Corp.

$97.43

0.78 (0.81%)

16:52
11/13/19
11/13
16:52
11/13/19
16:52
Hot Stocks
RLI Corp. declares special cash dividend of $1.00 per share »

Payable on December 20 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CPA

Copa Holdings

$107.71

1.89 (1.79%)

16:52
11/13/19
11/13
16:52
11/13/19
16:52
Hot Stocks
Copa Holdings reports Q3 load factor up 1.4pts to 85.6% »

Copa Holdings reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

XBIT

XBiotech

$11.42

0.18 (1.60%)

16:50
11/13/19
11/13
16:50
11/13/19
16:50
Recommendations
XBiotech analyst commentary  »

XBiotech price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$7.90

0.22 (2.86%)

16:50
11/13/19
11/13
16:50
11/13/19
16:50
Hot Stocks
Breaking Hot Stocks news story on American Outdoor Brands »

American Outdoor Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

16:48
11/13/19
11/13
16:48
11/13/19
16:48
Earnings
Copa Holdings reports Q3 EPS $2.45, consensus $2.23 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

, CGIX

Cancer Genetics

$2.93

-0.2 (-6.39%)

16:48
11/13/19
11/13
16:48
11/13/19
16:48
Hot Stocks
Interpace Diagnostics changes name to Interpace Biosciences »

Interpace Diagnostics…

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

CGIX

Cancer Genetics

$2.93

-0.2 (-6.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 07

    Dec

TPTX

Turning Point Therapeutics

$48.68

0.84 (1.76%)

16:46
11/13/19
11/13
16:46
11/13/19
16:46
Initiation
Turning Point Therapeutics initiated  »

Turning Point…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBPO

China Biologic

$116.87

1.17 (1.01%)

16:46
11/13/19
11/13
16:46
11/13/19
16:46
Earnings
China Biologic raises FY19 income growth outlook to 11%-13% from 4%-6% »

The company is raising…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CBPO

China Biologic

$116.87

1.17 (1.01%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Earnings
China Biologic reports Q3 adjusted EPS $1.40, one estimate 88c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Earnings
Breaking Earnings news story on Interpace Diagnostics »

Interpace Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

CSCO

Cisco

$48.44

0.06 (0.12%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Hot Stocks
Breaking Hot Stocks news story on Cisco »

Cisco down about 5% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 09

    Dec

  • 10

    Dec

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:44
11/13/19
11/13
16:44
11/13/19
16:44
Earnings
Interpace Diagnostics lowers 2019 revenue view to $28M-$32M from $33M-$36M »

Consensus for 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:43
11/13/19
11/13
16:43
11/13/19
16:43
Earnings
Interpace Diagnostics reports Q3 EPS (19c), consensus (19c) »

Reports Q3 revenue $7.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.